Gilenya
Named-patient access overview. Gilenya is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Gilenya (fingolimod) is an oral sphingosine 1-phosphate receptor modulator from Novartis, first approved by the US Food and Drug Administration in September 2010 and expanded to paediatric use in 2018. It is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and paediatric patients 10 years and older. Dosing is one 0.5 mg capsule taken orally once daily (0.25 mg for paediatric patients at or below 40 kg), with the first dose administered under cardiac monitoring per the US prescribing information. Treatment is initiated and managed by a neurologist with multiple sclerosis expertise.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Gilenya
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Gilenya is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Gilenya in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Gilenya
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.